AHA Scientific Sessions 2026 AbstractNov 7, 2026, 01:24 GMT

Blood sugar drugs linked to fewer heart and blood vessel events

At one year, users had a lower relative rate of major heart and blood vessel events than nonusers, with a hazard ratio of 0.40.

Paper by Rohit Ponnada, Yesh Dhruva, Nicholas Mootz, Michael Khorsandi, Chien-Jung Lin · Saint Louis Univ SOM · Dept of Internal Medicine-Cardiology

A whole heart beside a molecular chain and scarred kidney contrasts with a smaller damaged heart above an intact kidney.

Our read

Interventions

Studied:: Cohort study of adults older than 50 with cardiovascular risk factors, five years, against nonusers
What changed:: Major heart and blood vessel events were lower in users than nonusers at one year, with a hazard ratio of 0.40
The catch:: Matching could not rule out differences in underlying health or care between users and nonusers
In the record:: The 1,334th paper on GLP-1 receptor agonists with results in people; 4,739 on record in all. Its result on mortality agrees with 184 of 204 other findings on record; 1 points the other way and 19 found no change.
Why it’s aging research:: It studies an intervention with evidence of extending healthy life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper

Adults older than 50 with more than three documented cardiovascular risk factors but no established cardiovascular disease caused by fatty buildup in arteries were included in a retrospective cohort study. Researchers compared users and nonusers of glucagon-like peptide-1 receptor agonists, blood sugar-lowering drugs, across 112 US healthcare organizations. After matching on 29 characteristics, each group contained 165,923 people.

Drug use was associated with fewer major heart and blood vessel events, fewer deaths from any cause and less sepsis, a life-threatening response to infection, over five years. Rates of end-stage kidney failure were similar at one year but higher among users at three and five years. At five years, the relative rate was higher among users (hazard ratio 2.12), although absolute event rates remained low in both groups.

Why it matters

For older adults with cardiovascular risk factors, the question is whether these drugs can prevent a first major cardiovascular event. The authors called for prospective trials to test that possibility.

Caveats

Matching could not rule out differences in underlying health or care between users and nonusers, and the conference abstract did not provide absolute event rates. The results do not cover adults 50 or younger, people at lower cardiovascular risk or those with established cardiovascular disease caused by fatty buildup in arteries.